Kavon Karrobi

Kavon Karrobi

Auto-generated profile, based on publicly available information

Kavon Karrobi

Boston University, Department of Biomedical Engineering, Boston, Massachusetts, United States

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2014 in Journal of Controlled Release
Verified
Journal Article
Closed access
TTTerence Ta
Terence Ta
EBElizabeth Bartolak-Suki
Elizabeth Bartolak-Suki
EPEun-Joo Park
Eun-Joo Park
KKKavon Karrobi
Kavon Karrobi
NMNathan J McDannold
Nathan J McDannold
TPTyrone M. Porter
Tyrone M. Porter

10 January 2020 in Journal of Biomedical Optics
Verified
Journal Article
Open access
PDF file
MAMatthew B. Applegate
Matthew B. Applegate
KKKavon Karrobi
Kavon Karrobi
JAJoseph P. Angelo
Joseph P. Angelo
WAWyatt M. Austin
Wyatt M. Austin
STSyeda M. Tabassum
Syeda M. Tabassum
DRDarren M. Roblyer
Darren M. Roblyer
Spatial frequency domain imaging (SFDI) is a noninvasive, label-free, diffuse optical technique that can generate two-dimensional maps of the absorption coefficient (μa) and reduced scattering coefficient (μs′) of biological tissue. To accomplish this, SFDI utilizes sinusoidally modulated illumination patterns, which are projected onto the sample, and the remitted light is detected with a camera. A demodulation and calibration procedure is used to estimate the spatial modulation transfer function (MTF) of the sample. The MTF can then be fit to a computational model of photon transport to determine both μa and μs′ on a pixel-by-pixel basis.1 Knowledge of μa at several different carefully chosen wavelengths allows for the molar concentration of tissue chromophores such as oxyhemoglobin and deoxyhemoglobin to be estimated. Both optical properties and chromophore concentrations can then be used as optical biomarkers for a wide range of applications.

18 January 2018 in Biomedical Optics Express
Verified
Journal Article
Open access
PDF file
VPVivian Pera
Vivian Pera
KKKavon Karrobi
Kavon Karrobi
STSyeda Tabassum
Syeda Tabassum
Fei TengFei Teng
Fei Teng
DRDarren Roblyer
Darren Roblyer
Spatial frequency domain imaging (SFDI) is a wide-field diffuse optical imaging modality that has attracted considerable interest in recent years. Typically, diffuse reflectance measurements of spatially modulated light are used to quantify the optical absorption and reduced scattering coefficients of tissue, and with these, chromophore concentrations are extracted. However, uncertainties in estimated absorption and reduced scattering coefficients are rarely reported, and we know of no method capable of providing these when look-up table (LUT) algorithms are used to recover the optical properties. We present a method to generate optical property uncertainty estimates from knowledge of diffuse reflectance measurement errors. By employing the Cramér-Rao bound, we can quickly and efficiently explore theoretical SFDI performance as a function of spatial frequencies and sample optical properties, allowing us to optimize spatial frequency selection for a given application. In practice, we can also obtain useful uncertainty estimates for optical properties recovered with a two-frequency LUT algorithm, as we demonstrate with tissue-simulating phantom and in vivo experiments. Finally, we illustrate how absorption coefficient uncertainties can be propagated forward to yield uncertainties for chromophore concentrations, which could significantly impact the interpretation of experimental results.

1 March 2021 in Neoplasia
Verified
Journal Article
Open access
STSyeda Tabassum
Syeda Tabassum
ATAnup Tank
Anup Tank
FWFay Wang
Fay Wang
KKKavon Karrobi
Kavon Karrobi
CVCameron Vergato
Cameron Vergato
DRDarren Roblyer
Darren Roblyer
Monitoring of the in vivo tumor state to track therapeutic response in real time may help to evaluate new drug candidates, maximize treatment efficacy, and reduce the burden of overtreatment. Current preclinical tumor imaging methods have largely focused on anatomic imaging (e.g., MRI, ultrasound), functional imaging (e.g., FDG-PET), and molecular imaging with exogenous contrast agents (e.g., fluorescence optical tomography). Here we utalize spatial frequency domain imaging (SFDI), a noninvasive, label-free optical technique, for the wide-field quantification of changes in tissue optical scattering in preclinical tumor models during treatment with chemotherapy and antiangiogenic agents. Optical scattering is particularly sensitive to tissue micro-architectural changes, including those that occur during apoptosis, an early indicator of response to cytotoxicity induced by chemotherapy, thermotherapy, cryotherapy, or radiation therapy. We utilized SFDI to monitor responses of PC3/2G7 prostate tumors and E0771 mammary tumors to treatment with cyclophosphamide or the antiangiogenic agent DC101 for up to 49 days. The SFDI-derived scattering amplitude was highly correlated with cleaved caspase-3, a marker of apoptosis (ρp = 0.75), while the exponent of the scattering wavelength-dependence correlated with the cell proliferation marker PCNA (ρp = 0.69). These optical parameters outperformed tumor volume and several functional parameters (e.g., oxygen saturation and hemoglobin concentration) as an early predictive biomarker of treatment response. Quantitative diffuse optical scattering is thus a promising new early marker of treatment response, which does not require radiation or exogenous contrast agents.

31 January 2019 in Journal of Biophotonics
Verified
Journal Article
Closed access
PDF file
KKKavon Karrobi
Kavon Karrobi
ATAnup Tank
Anup Tank
STSyeda Tabassum
Syeda Tabassum
VPVivian Pera
Vivian Pera
DRDarren Roblyer
Darren Roblyer

25 May 2023 in Biomedical Optics Express
Verified
Journal Article
Closed access
APAnahita Pilvar
Anahita Pilvar
AMAarohi M. Mehendale
Aarohi M. Mehendale
KKKavon Karrobi
Kavon Karrobi
FEFatima El-Adili
Fatima El-Adili
ABAndreea Bujor
Andreea Bujor
DRDarren Roblyer
Darren Roblyer
Systemic sclerosis (SSc) is an autoimmune disease characterized by the widespread deposition of excess collagen in the skin and internal organs, as well as vascular dysfunction. The current standard of care technique used to quantify the extent of skin fibrosis in SSc patients is the modified Rodnan skin score (mRSS), which is an assessment of skin thickness based on clinical palpation. Despite being considered the gold standard, mRSS testing requires a trained physician and suffers from high inter-observer variability. In this study, we evaluated the use of spatial frequency domain imaging (SFDI) as a more quantitative and reliable method for assessing skin fibrosis in SSc patients. SFDI is a wide-field and non-contact imaging technique that utilizes spatially modulated light to generate a map of optical properties in biological tissue. The SFDI data were collected at six measurement sites (left and right forearms, hands, and fingers) of eight control subjects and ten SSc patients. mRSS were assessed by a physician, and skin biopsies were collected from subject’s forearms and used to assess for markers of skin fibrosis. Our results indicate that SFDI is sensitive to skin changes even at an early stage, as we found a significant difference in the measured optical scattering (μs′) between healthy controls and SSc patients with a local mRSS score of zero (no appreciable skin fibrosis by gold standard). Furthermore, we found a strong correlation between the diffuse reflectance (R d ) at a spatial frequency of 0.2 mm−1 and the total mRSS between all subjects (Spearman correlation coefficient = -0.73, p-value < 0.0028), as well as high correlation with histology results. The healthy volunteer results show excellent inter- and intra-observer reliability (ICC > 0.8). Our results suggest that the measurement of tissue μs′ and R d at specific spatial frequencies and wavelengths can provide an objective and quantitative assessment of skin involvement in SSc patients, which could greatly improve the accuracy and efficiency of monitoring disease progression and evaluating drug efficacy.